Skip to content

Long-Term outcome of bilateral ureteronephrectomy for aristolochic acid nephropathy

Long-Term outcome of bilateral ureteronephrectomy for aristolochic acid nephropathy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ORC-17013166
Enrollment
Unknown
Registered
2017-10-30
Start date
2017-11-01
Completion date
Unknown
Last updated
2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aristolochic acid nephropathy

Interventions

Case series:post underwent unilateral ureteronephrectomy

Sponsors

The First Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: In year 1998-2015,The patients undergoing renal replacement therapy in out hospital because of end-stage aristolochic acid nephropathy who had occured upper urinary tract tumors.;Inclusion criteria: In year 1998-2015,The patients undergoing renal replacement therapy in out hospital because of end-stage aristolochic acid nephropathy who had occured upper urinary tract tumors.;Inclusion criteria: In year 1998-2015,The patients undergoing renal replacement therapy in out hospital because of end-stage aristolochic acid nephropathy who had occured upper urinary tract tumors.;Inclusion criteria: In year 1998-2015,The patients undergoing renal replacement therapy in out hospital because of end-stage aristolochic acid nephropathy who had occured upper urinary tract tumors.;Inclusion criteria: In year 1998-2015,The patients undergoing renal replacement therapy in out hospital because of end-stage aristolochic acid nephropathy who had occured upper urinary tract tumors.

Exclusion criteria

Exclusion criteria: patient who has a tumor elsewhere;Exclusion criteria: patient who has a tumor elsewhere;Exclusion criteria: patient who has a tumor elsewhere;Exclusion criteria: patient who has a tumor elsewhere;Exclusion criteria: patient who has a tumor elsewhere

Design outcomes

Primary

MeasureTime frame
Age at diagnosis as AAN;Age at when begin renal replacement;

Countries

China

Contacts

Public ContactYan Zhang;Yan Zhang;Yan Zhang;Yan Zhang;Yan Zhang ;;;;

Department of Transplantation, the First Affiliated Hospital of Wenzhou Medical University;Department of Transplantation, the First Affiliated Hospital of Wenzhou Medical University;Department of Transplantation, the First Affiliated Hospital of Wenzhou Medical University;Department of Transplantation, the First Affiliated Hospital of Wenzhou Medical University;Department of Transplantation, the First Affiliated Hospital of Wenzhou Medical University

29369153@qq.com;29369153@qq.com;29369153@qq.com;29369153@qq.com;29369153@qq.com+86 15858583023;+86 15858583023;+86 15858583023;+86 15858583023;+86 15858583023

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026